Aelis Farma SA - Asset Resilience Ratio
Aelis Farma SA (AELIS) has an Asset Resilience Ratio of 69.27% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check AELIS strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2022)
This chart shows how Aelis Farma SA's Asset Resilience Ratio has changed over time. See Aelis Farma SA (AELIS) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Aelis Farma SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Aelis Farma SA worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €10.79 Million | 69.27% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €10.79 Million | 69.27% |
Asset Resilience Insights
- Very High Liquidity: Aelis Farma SA maintains exceptional liquid asset reserves at 69.27% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Aelis Farma SA Industry Peers by Asset Resilience Ratio
Compare Aelis Farma SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hugel Inc
KQ:145020 |
Biotechnology | 29.57% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Absci Corp
NASDAQ:ABSI |
Biotechnology | 59.86% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for Aelis Farma SA (2018–2022)
The table below shows the annual Asset Resilience Ratio data for Aelis Farma SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 87.79% | €34.43 Million ≈ $40.25 Million |
€39.22 Million ≈ $45.85 Million |
+0.52pp |
| 2021-12-31 | 87.27% | €24.71 Million ≈ $28.89 Million |
€28.31 Million ≈ $33.10 Million |
+7.34pp |
| 2019-12-31 | 79.93% | €5.77 Million ≈ $6.75 Million |
€7.22 Million ≈ $8.44 Million |
-1.31pp |
| 2018-12-31 | 81.24% | €5.12 Million ≈ $5.99 Million |
€6.30 Million ≈ $7.37 Million |
-- |
About Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; an… Read more